DK0772451T3 - Behandling af type II-diabetes mellitus med amylin-agonister - Google Patents

Behandling af type II-diabetes mellitus med amylin-agonister

Info

Publication number
DK0772451T3
DK0772451T3 DK96921467T DK96921467T DK0772451T3 DK 0772451 T3 DK0772451 T3 DK 0772451T3 DK 96921467 T DK96921467 T DK 96921467T DK 96921467 T DK96921467 T DK 96921467T DK 0772451 T3 DK0772451 T3 DK 0772451T3
Authority
DK
Denmark
Prior art keywords
diabetes mellitus
type
treatment
amylin agonists
amylin
Prior art date
Application number
DK96921467T
Other languages
English (en)
Inventor
Orville G Kolterman
Robert G Thompson
John F Mullane
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of DK0772451T3 publication Critical patent/DK0772451T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK96921467T 1995-06-07 1996-06-07 Behandling af type II-diabetes mellitus med amylin-agonister DK0772451T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/483,188 US6143718A (en) 1995-06-07 1995-06-07 Treatment of Type II diabetes mellutis with amylin agonists
PCT/US1996/009875 WO1996040220A1 (en) 1995-06-07 1996-06-07 Treatment of type ii diabetes mellitus with amylin agonists

Publications (1)

Publication Number Publication Date
DK0772451T3 true DK0772451T3 (da) 2003-01-06

Family

ID=23919034

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96921467T DK0772451T3 (da) 1995-06-07 1996-06-07 Behandling af type II-diabetes mellitus med amylin-agonister

Country Status (19)

Country Link
US (2) US6143718A (da)
EP (1) EP0772451B1 (da)
JP (1) JP4009319B2 (da)
AT (1) ATE228849T1 (da)
AU (1) AU721489B2 (da)
BG (1) BG101230A (da)
CA (1) CA2196999C (da)
CZ (1) CZ289043B6 (da)
DE (1) DE69625157T2 (da)
DK (1) DK0772451T3 (da)
ES (1) ES2187659T3 (da)
HU (1) HUP9700368A3 (da)
IN (1) IN181672B (da)
NO (1) NO970519L (da)
PT (1) PT772451E (da)
RU (1) RU2166958C2 (da)
SK (1) SK18697A3 (da)
WO (1) WO1996040220A1 (da)
ZA (1) ZA964838B (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
CZ69596A3 (en) * 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO1999034822A1 (en) * 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
AU2003235742B2 (en) * 2002-01-08 2008-08-07 Amylin Pharmaceuticals, Llc Use of Amylin agonists to modulate triglycerides
WO2004004665A2 (en) * 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
WO2004104018A2 (en) * 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
US8501473B2 (en) * 2003-07-16 2013-08-06 Evotec International Gmbh Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
US8114958B2 (en) * 2004-02-11 2012-02-14 Amylin Pharmaceuticals, Inc. Amylin family peptides
CA2556923A1 (en) * 2004-02-20 2005-09-09 Rinat Neuroscience Corp. Methods of treating obesity or diabetes using nt-4/5
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
EP1888043A4 (en) * 2005-03-11 2010-07-28 Endo Pharmaceuticals Solutions OCTREOTIDE FORMULATIONS WITH CONTROLLED RELEASE
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
AU2007210862A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist
JP2009525319A (ja) * 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
CN101605556A (zh) * 2006-12-20 2009-12-16 瑞纳神经科学公司 治疗自体免疫疾病的trkb激动剂
EA201070609A1 (ru) * 2007-11-14 2010-12-30 Амилин Фармасьютикалз, Инк. Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
JP5622725B2 (ja) * 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． エキセナチド及び他のポリペプチド類の持続的送達
AU2009262263B2 (en) * 2008-06-25 2014-08-14 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
CA2740685C (en) 2008-10-17 2018-09-11 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
AU2010223329B2 (en) * 2009-03-12 2016-07-21 Keybioscience Ag Treatment of diabetes and metabolic syndrome
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
ES2887370T3 (es) * 2014-09-04 2021-12-22 Novo Nordisk As Nuevo agonista del receptor de amilina y calcitonina
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5367052A (en) * 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
ATE205854T1 (de) * 1991-11-19 2001-10-15 Amylin Pharmaceuticals Inc Peptide als amylin-agonisten und ihre verwendung
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
CZ69596A3 (en) * 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides

Also Published As

Publication number Publication date
DE69625157D1 (de) 2003-01-16
CA2196999C (en) 2012-09-04
EP0772451A4 (en) 1998-09-30
ES2187659T3 (es) 2003-06-16
NO970519D0 (no) 1997-02-05
CZ289043B6 (cs) 2001-10-17
EP0772451A1 (en) 1997-05-14
US6417164B1 (en) 2002-07-09
BG101230A (en) 1997-10-31
DE69625157T2 (de) 2003-04-17
SK18697A3 (en) 1998-02-04
JP4009319B2 (ja) 2007-11-14
HU9700368D0 (en) 1997-04-28
CZ33797A3 (en) 1997-07-16
JPH10503785A (ja) 1998-04-07
ZA964838B (en) 1997-02-24
EP0772451B1 (en) 2002-12-04
ATE228849T1 (de) 2002-12-15
US6143718A (en) 2000-11-07
HUP9700368A2 (hu) 1998-06-29
AU721489B2 (en) 2000-07-06
PT772451E (pt) 2003-04-30
IN181672B (da) 1998-08-29
RU2166958C2 (ru) 2001-05-20
CA2196999A1 (en) 1996-12-19
HUP9700368A3 (en) 2001-03-28
WO1996040220A1 (en) 1996-12-19
NO970519L (no) 1997-04-07
AU6268596A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
DK0772451T3 (da) Behandling af type II-diabetes mellitus med amylin-agonister
EA200200503A1 (ru) Способ лечения ревматоидного артрита
DK0867178T3 (da) Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser
EA199800316A1 (ru) СЕЛЕКТИВНЫЕ β-АДРЕНЕРГИЧЕСКИЕ АГОНИСТЫ
AU1718400A (en) Method for treating pain
EA199800626A1 (ru) Применение агониста ppar-гамма для лечения синдрома х
DK0514452T4 (da) Anvendelse af insulin-sensibiliserende midler til behandling af hypertension
EE03202B1 (et) Intravaginaalne manustussüsteem ja selle valmistamismeetod
PT97615A (pt) Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii
DE68910799D1 (de) Faserbehandlungszusammensetzung.
DK0863760T3 (da) Anvendelse af forbindelser med antimineralcorticoid virkning over for narkotikafvænning
DE69112166D1 (de) Plasmaquellenvorrichtung für Ionenimplantierung.
FI951511A (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DK322583D0 (da) Middel til behandling af sar
EA200100133A1 (ru) Оксазолидиноны для лечения инфекционных болезней глаз
PT888330E (pt) Metodos de tratamento ou prevencao de cistite intersticial
ES2062762T3 (es) Metodo para tratar el choque septico.
DK0517787T3 (da) Fremgangsmåde til behandling af terapiresistent skizofreni med amperozide
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
EA199800822A1 (ru) Способ лечения избыточной агрессии
KR920001467U (ko) 결합식 용액 주입기(syinge)용 팁(tip)
NO993069L (no) Ny anvendelse av dipeptider
EA199800818A1 (ru) Способ лечения бессонницы
EA200000418A1 (ru) Применение тиазолидиндионов для лечения гипергликемии